Hematologic Malignancy
Alkylating Agent-Related Myelodysplastic Syndrome
CI-CAN-00004429Explore in graph →
Hematologic
- NCIt
- C7643
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004429Explore in graph →
Data completeness0 / 7 dimensions
Computed from entity_counters.completeness · refreshed after each connector run
Definition
A disorder seen following cancer chemotherapy. It is the most common cause of therapy-related myelodysplastic syndromes. It typically manifests several years after initiation of single or multi-agent chemotherapy with alkylators. Mutagenic potential of alkylating agents is believed to be age and cumulative dose-dependent. Deletions in chromosomes 5 and 7 are associated with susceptibility to this disorder. Clinical signs may include fatigue, dyspnea, bruising and frequent infections. Clinical course may progress to bone marrow failure or acute myeloid leukemia that is refractory to treatment. Prognosis is dismal with survivability usually less than one year.
Data updated 22 days agoSource updated 26.08e
Taxonomy
Several hierarchies coexist; edges are listed per hierarchy type with their source.
Parents
Children (0)
Leaf node — no children.
Anatomy
Data updated 6 hours agoSource updated unknowncounters aggregate over descendants
Names
CancerIndex is a research and information platform. It does not diagnose and does not recommend treatment.
Key figures
Each figure carries its unit, period and source; ranks link to "Why this rank?".
Data updated 6 hours agoSource updated unknownregistry figures: cdc-uscs · latest year available per metric · counters aggregate over descendants